July 31 (Reuters) – AbbVie trimmed its 2026 profit forecast on Friday to account for its planned Apogee Therapeutics acquisition, while topping second-quarter estimates on strong immunology drug sales
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Saudi civil defense issues alert over potential danger in Jazan
CAIRO, Nov 7 (Reuters) - The Saudi civil defense on Saturday issued an alert over…
Binance CFO Kaiser Ng steps down, Justin Yek named new finance chief
Nov 7 (Reuters) - Binance's finance chief Kaiser Ng is leaving the company to pursue…
Binance CFO Kaiser Ng steps down, Justin Yek named new finance chief
Nov 7 (Reuters) - Binance's finance chief Kaiser Ng is leaving the company to pursue…
